Effects of Aerobic Exercise on The Six Minutes Walking Test and Quality of Life in EGFR Mutation Non-Small Cell Lung Cancer Patients
DOI:
https://doi.org/10.36497/jri.v45i2.613Keywords:
6MWT, adenocarcinoma, aerobic exercise, FACT-L, quality of lifeAbstract
Background: Lung cancer reduces lung function, muscle mass, and psychological well-being, which lowers exercise capacity and quality of life. Pulmonary rehabilitation, such as aerobic exercise, can improve exercise capacity and the quality of life (QoL) in lung cancer patients. This study aimed to investigate the influence of aerobic exercise on the six-minute walking test (6MWT) and the quality of life of lung cancer patients.
Methods: A clinical trial with a quasi-experimental, pretest, and post-test design was conducted on stage ≥IVa adenocarcinoma lung cancer patients who were receiving outpatient targeted therapy at the pulmonary clinic of Dr. Moewardi General Hospital for ≥1 month starting from May 2023, until the required sample size was met. The 6MWT and Functional Assessment of Cancer Therapy-Lung (FACT-L) were measured at the baseline and eight weeks ±2 weeks after aerobic exercise by walking about 15-20 minutes and breathing exercises.
Results: The study included fourteen patients in the control group and fifteen patients in the aerobic group. The mean difference of 6MWT between the control and the aerobic group was 38.33 m. Functional, lung cancer subscale (LCS), total, and TOI in FACT-L showed significant differences in the increment pre-test and post-test between the control and aerobic group (P<0.05), with significant differences in pre-test and post-test of most categories in both groups, except for social.
Conclusion: Aerobic exercise, psychological support, and nutrition have significantly improved the 6MWT and quality of life in lung cancer patients.
Downloads
References
1. Neal RD, Sun F, Emery JD, Callister ME. Lung cancer. BMJ. 2019;365:l1725.
2. Bye A, Sjøblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, et al. Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759–67.
3. Dela Cruz CS, Tanoue LT, Matthay RA. Epidemiology of lung cancer. In: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, et al., editors. Fishman’s Pulmonary Diseases and Disorders, 5e. New York, NY: McGraw-Hill Education; 2015. p. 1652–83.
4. Cavalheri V, Granger CL. Exercise training as part of lung cancer therapy. Respirology. 2020;25(Suppl 2):80–7.
5. Perhimpunan Dokter Paru Indonesia. Pedoman diagnosis dan penatalaksanaan di Indonesia. In: Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S, editors. Kanker paru. 2015th ed. Jakarta: UI Press; 2018. p. 1–20.
6. Mota RT, Ferreira Júnior HM, Pereira FS, Vieira MA, Costa S de M. Quality of life of patients with lung cancer: A scoping review. Rev Bras Geriatr Gerontol. 2019;22(2):e180162.
7. Spruit M, Nici L. Current concepts and definitions. In: Clini E, Holland AE, Pitta F, Troosters T, editors. Textbook of pulmonary rehabilitation. 1st ed. Cham: Springer; 2018. p. 19–22.
8. Holland AE, Singh SJ, Casaburi R, Clini E, Cox NS, Galwicki M, et al. Defining modern pulmonary rehabilitation: An official American thoracic society workshop report. Ann Am Thorac Soc. 2021;18(5):e12–29.
9. Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, et al. Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled? Oncologist. 2020;25(3):e555-69.
10. Apriliana D, Suradi S, Setijadi AR. Role of incentive spirometry on exercise capacity, breathing symptoms, depression rate, and quality of life in NSCLC patients with chemotherapy. Respiratory Science. 2021;2(1):8–17.
11. Hsu WH, Yang JCH, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(Suppl 1):i3-9.
12. Yoon HY, Ryu JS, Sim YS, Kim D, Lee SY, Choi J, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS One. 2020;15(2):e0228925.
13. Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89.
14. Jones LW, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M, et al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer. 2012;76(2):248–52.
15. Hwang CL, Yu CJ, Shih JY, Yang PC, Wu YT. Effects of exercise training on exercise capacity in patients with non-small cell lung cancer receiving targeted therapy. Support Care Cancer. 2012;20(12):3169–77.
16. Wang Q, Zhou W. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. J Sport Health Sci. 2021;10(2):201–10.
17. Lin YY, Liu MF, Tzeng JI, Lin CC. Effects of walking on quality of life among lung cancer patients: A longitudinal study. Cancer Nurs. 2015;38(4):253–9.
18. Gerritsen JKW, Vincent AJPE. Exercise improves quality of life in patients with cancer: A systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2016;50(13):796–803.
19. Egegaard T, Rohold J, Lillelund C, Persson G, Quist M. Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study. Rep Pract Oncol Radiother. 2019;24(4):375–82.
20. Dhillon HM, Bell ML, van der Ploeg HP, Turner JD, Kabourakis M, Spencer L, et al. Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: A randomized controlled trial. Ann Oncol. 2017;28(8):1889–97.
21. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609.
22. El-Kader SMA, Al-Shreef FM, Al-Jiffri OH. Impact of aerobic exercise versus resisted exercise on endothelial activation markers and inflammatory cytokines among elderly. Afr Health Sci. 2019;19(4):2874–80.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lia Priscilia Sibarani, Ana Rima Setijadi, Hendrastutik Apriningsih, Harsini Harsini, A. Farih Raharjo, Yusup Subagio Sutanto
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
